Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Individuals with type 2 diabetes mellitus (T2DM) are at increased risk for cardiovascular
events (for example, heart attack) and the risk is related to one's overall control of blood
glucose levels. In this study the investigators will measure the effects of saxagliptin,
compared to placebo, before, during, and after coronary artery bypass graft (CABG) surgery.
The investigators will use samples of the patients' blood and tissue to measure and evaluate
indicators of the body's response to the treatment. This study is being done to evaluate the
effect of saxagliptin on biomarkers of the heart to help us understand whether reducing or
controlling a person's blood glucose levels during and after CABG surgery will produce better
clinical outcomes (for example, better heart health).